PTPN11 and neoplasm: Given the potential dual role in the initiation and advancement of distinct solid tumors, the outcomes are contingent on the specific engagement of SHP2 with primary signaling pathways—acting either as a tumor suppressor or as an oncogenic tumor promoter (6–8).